Related Experiment Videos
Fondaparinux, the first selective factor Xa inhibitor
Alexander G G Turpie1, Bengt I Eriksson, Michael R Lassen
1Hamilton Health Sciences-General Hospital, Hamilton, Ontario, Canada. turpiea@mcmaster.ca
Current Opinion in Hematology
|August 13, 2003
Summary
Fondaparinux, a synthetic antithrombotic, effectively prevents venous thromboembolism (VTE) after orthopedic surgery. It shows superior efficacy over enoxaparin with similar bleeding risk, offering a predictable and safe VTE prophylaxis.
Area of Science:
- Pharmacology
- Thrombosis Research
- Drug Development
Background:
- Fondaparinux is a novel synthetic pentasaccharide anticoagulant.
- It selectively inhibits factor Xa, representing a new class of antithrombotic agents.
- Its linear pharmacokinetics allow for once-daily subcutaneous dosing.
Purpose of the Study:
- To evaluate the efficacy and safety of fondaparinux in VTE prophylaxis.
- To compare fondaparinux with enoxaparin in orthopedic surgery patients.
- To assess the impact of extended prophylaxis duration on VTE risk.
Main Methods:
- Clinical trials involving patients undergoing orthopedic surgery.
- Comparison of fondaparinux versus enoxaparin for VTE prophylaxis.
- Assessment of bleeding incidence and VTE events.
Main Results:
- Fondaparinux reduced VTE risk by over 50% compared to enoxaparin.
- No significant difference in clinically important bleeding was observed.
- Extended fondaparinux prophylaxis (4 weeks) reduced VTE risk by 96% post-hip fracture surgery.
Conclusions:
- Fondaparinux is a highly effective and safe option for VTE prophylaxis in orthopedic surgery.
- Its predictable profile and efficacy support its use in VTE prevention.
- Further research suggests promise in treating VTE and acute coronary syndromes.